Disc Medicine Inc.
$ 93.79
1.53%
04 Dec - close price
- Market Cap 3,487,360,000 USD
- Current Price $ 93.79
- High / Low $ 94.58 / 91.22
- Stock P/E N/A
- Book Value 16.38
- EPS -5.37
- Next Earning Report 2026-03-27
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.35 %
- 52 Week High 97.11
- 52 Week Low 30.82
About
Disc Medicine Inc. (IRON) is a clinical-stage biotechnology company based in Watertown, Massachusetts, focused on developing transformative therapies for patients suffering from serious hematologic disorders. With a robust pipeline targeting key unmet medical needs in hematology, the company employs cutting-edge drug development techniques grounded in extensive scientific research. Disc Medicine is poised to advance treatment paradigms within this critical therapeutic area, underlining its commitment to improving patient outcomes through innovative and transformative solutions.
Analyst Target Price
$118.17
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-11 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -1.77 | -1.58 | -1.02 | -0.98 | -0.8885 | -1.03 | -1.09 | -0.9 | -0.58 | -0.74 | -1.2 | -1.22 |
| Estimated EPS | -1.48 | -1.12 | -1.0738 | -1.1036 | -1.05 | -1.11 | -1 | -0.78 | -0.8 | -0.86 | -0.68 | -0.76 |
| Surprise | -0.29 | -0.46 | 0.0538 | 0.1236 | 0.1615 | 0.08 | -0.09 | -0.12 | 0.22 | 0.12 | -0.52 | -0.46 |
| Surprise Percentage | -19.5946% | -41.0714% | 5.0102% | 11.1997% | 15.381% | 7.2072% | -9% | -15.3846% | 27.5% | 13.9535% | -76.4706% | -60.5263% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-27 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -1.67 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRON
2025-10-30 00:00:00
WilmerHale advised the underwriters in a $287.5 million public offering for Disc Medicine, Inc. The offering included the sale of common stock and pre-funded warrants by Disc, and a sale of common stock by one of Disc's stockholders, AI DMI LLC. Disc Medicine is a clinical stage biopharmaceutical company focused on treatments for serious hematologic diseases.
2025-10-19 14:27:32
Cantor Fitzgerald has increased its price target for Disc Medicine (NASDAQ:IRON) to $153.00, indicating strong price appreciation for the stock. This follows several other analyst upgrades and "buy" ratings, leading to a consensus "Moderate Buy" rating and an average target price of $108.73. Institutional investors and insiders have also shown increased activity, with significant boosts in holdings by major hedge funds.
2025-10-19 00:42:02
Stock Traders Daily's AI models indicate that Disc Medicine Inc. (NASDAQ: IRON) is experiencing significant volatility with a breakout underway. Key findings show strong near and mid-term sentiment but elevated downside risk. The article outlines specific AI-generated trading strategies including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
2025-10-18 15:36:24
Disc Medicine's stock (NASDAQ:IRON) gapped up following positive analyst upgrades including a "buy" rating from Truist Financial with an $86.00 price objective. Other firms like Wedbush and Raymond James Financial also increased their target prices and maintained "outperform" or "strong-buy" ratings. Institutional investors have significantly increased their stakes in the company, which saw its stock trading up by 21.0%.
2025-10-18 08:46:32
Disc Medicine is scheduled to present data on its drug candidate DISC-0974 at the upcoming ASN Kidney Week. The presentation will focus on the drug's efficacy and safety, particularly for patients with kidney-related conditions. This event is significant for investors and medical professionals tracking developments in kidney disease treatments.
2025-10-18 02:37:02
Disc Medicine Director Kevin Bitterman recently sold 93,585 shares of company stock for over $8 million. This transaction follows a significant 25.5% increase in Disc Medicine's stock price after receiving an FDA Commissioner’s National Priority Voucher for its drug bitopertin, which has led several analysts to raise their price targets. TipRanks' AI Analyst, Spark, indicates a "Neutral" outlook for IRON stock due to early-stage biotechnology challenges despite a strong cash position.
